920023-54-7

Basic information

• Product Name: Spiro[1H-isoindole-1,4'-piperidine]-1'-carboxylic acid, 2,3-dihydro-3-oxo-, 1,1-dimethylethyl ester
• CAS NO: 920023-54-7
• Molecular Formula: C17H22N2O3
• Molecular Weight: 302.373
• Mol File: 920023-54-7.mol

Chemical Properties

• CAS DataBase Reference: Spiro[1H-isoindole-1,4'-piperidine]-1'-carboxylic acid, 2,3-dihydro-3-oxo-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Spiro[1H-isoindole-1,4'-piperidine]-1'-carboxylic acid, 2,3-dihydro-3-oxo-, 1,1-dimethylethyl ester(920023-54-7)
• EPA Substance Registry System: Spiro[1H-isoindole-1,4'-piperidine]-1'-carboxylic acid, 2,3-dihydro-3-oxo-, 1,1-dimethylethyl ester(920023-54-7)

Safety Data

• Hazardous Substances Data: 920023-54-7(Hazardous Substances Data)

Upstream product

• 937254-73-4 1'-tert-butyloxycarbonyl-2-(4-methoxybenzyl)-2',3'-dihydro-1'H-spiro[isoindoline-1,4'-pyridine]-3-one 
• 609-67-6 2-Iodobenzoyl chloride 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 788812-21-5 spiro[isoindole-1,4’-piperidin]-3(2H)-one 
• 328233-02-9 tert-butyl 2-benzyl-3-oxo-2,2',3,3'-tetrahydro-1'H-spiro[isoindole-1,4'-pyridine]-1'-carboxylate 
• 920023-53-6 4-azidocarbonyl-4-(2-bromo-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 920023-55-8 1'-tert-butyloxycarbonylspiro[isoindoline-1,4'-piperidine] 

Relevant articles and documents

Histone Deacetylase Inhibitors and Methods of Use Thereof

The present invention relates to methods of modulating activity of histone deacetylases (HDACs). The present invention also relates to methods of treating HDAC-associated diseases including, but not limited to, cancers, inflammatory disorders, and neurodegenerative disorders. The present invention also provides novel compounds and compositions thereof and methods of preparation of the same. The present invention also includes methods of inhibiting HDACs, and methods of treating HDAC-associated diseases using the compounds of the invention.

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

This invention relates to novel compounds of the Formula (I*), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11

INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS

The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

Spiro compounds

Spiro compounds of the general formula (I): wherein Ar1represents an optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V and W each represent a nitrogen atom or an optionally substituted methine group, wherein at least two of which represent said methine group; X represents methine; Y represents an optionally substituted imino or oxygen atom. These novel spiro compounds exhibit neuropeptide Y receptor (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, cardiovascular disorders, central nervous system disorders, metobolic diseases and the like.